SEARCH

SEARCH BY CITATION

References

  • 1
    Ladhani S, Aibara RJ, Riordan FAI, Shingadia D. Imported malaria in children: a review of clinical studies. Lancet Infect Dis 2007; 7: 349357.
  • 2
    Marais BJ, Schaaf HS. Childhood tuberculosis: an emerging and previously neglected problem. Infect Dis Clin North Am 2010; 24: 727749.
  • 3
    Swaminathan S, Rekha B. Pediatric tuberculosis: global overview and challenges. Clin Infect Dis 2010; 50: (Suppl. 3): S184194.
  • 4
    Cruz AT, Starke JR. Pediatric tuberculosis. Pediatr Rev 2010; 31: 1325.
  • 5
    Measles outbreaks and progress towards meeting measles pre-elimination goals: WHO African Region,2009–2010. Wkly Epidemiol Rec 2011; 86: 129136.
  • 6
    Centers for Disease Control and Prevention (CDC). Tracking progress toward global polio eradication-worldwide, 2009–2010. MMWR Morb Mortal Wkly Rep 2011; 60: 441445.
  • 7
    Steffen R. Influenza in travelers: epidemiology, risk, prevention, and control issues. Curr Infect Dis Rep 2010; 12: 181185.
  • 8
    Boggild AK, Castelli F, Gautret P, Torresi J, von Sonnenburg F, Barnett ED, Greenaway CA, Lim P-L, Schwartz E, Wilder-Smith A, Wilson ME, for the GeoSentinel Surveillance Network. Vaccine preventable diseases in returned international travelers: results from the GeoSentinel Surveillance Network. Vaccine 2010; 28: 73897395.
  • 9
    Chokshi D, Kesselheim A. Rethinking global access to vaccines. BMJ 2008; 336: 750753.
  • 10
    Jeong S-H, Lee H-S. Hepatitis A: clinical manifestations and management. Intervirology 2010; 53: 1519.
  • 11
    Fiore AE, Wasley A, Bell BP. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006; 55: (RR-7): 123.
  • 12
    Koff R. Hepatitis A. Lancet 1998; 351: 16431649.
  • 13
    Innis BL, Snitbhan R, Kunasol P, Laorakpongse T, Poopatanakool W, Kozik CA, Suntayakorn S, Suknuntapong T, Safary A, Tang D, Boslego JW. Protection against hepatitis A by an inactivated vaccine. JAMA 1994; 271: 13281334.
  • 14
    Iwarson S, Lindh M, Widerström L. Excellent booster response 4 to 8 years after a single primary dose of an inactivated hepatitis A vaccine. J Travel Med 2004; 11: 120121.
  • 15
    Landry P, Tremblay S, Darioli R, Genton B. Inactivated hepatitis A vaccine booster given >/=24 months after the primary dose. Vaccine 2000; 19: 399402.
  • 16
    Damme PV, Banatvala J, Fay O, Iwarson S, McMahon B, Herck KV, Shouval D, Bonanni P, Connor B, Cooksley G, Leroux-Roels G, Von Sonnenburg F, the International Consensus Group on Hepatitis A Virus Immunity. Consensus statement Hepatitis A booster vaccination: is there a need? Lancet 2003; 362: 10651071.
  • 17
    Van Damme PA, Van Herck K, Banatvala JE. Do we need hepatitis A booster vaccinations? J Travel Med 2004; 11: 179180.
  • 18
    Meltzer E, Schwartz E. Enteric fever: a travel medicine oriented view. Curr Opin Infect Dis 2010; 23: 432437.
  • 19
    Connor BA, Schwartz E. Typhoid and paratyphoid fever in travellers. The Lancet Infect Dis 2005; 5: 623628.
  • 20
    Basnyat B, Maskey AP, Zimmerman MD, Murdoch DR. Enteric (typhoid) fever in travelers. Clin Infect Dis 2005; 41: 14671472.
  • 21
    Typhoid. In: National Health and Medical Research Council (NHMRC). The Australian Immunisation Handbook, ed. Commonwealth of Australia. Canberra, ACT: Australian Government Department of Health and Ageing, 2008; 303308.
  • 22
    Levine MM. Typhoid fever vaccines. In: Vaccines, eds Plotkin S , Orenstein W , Offit P . Philadelphia, PA: Saunders, 2008; 887914.
  • 23
    Ferreccio C, Levine M, Rodriguez H, Contreras R. Comparative efficacy of two, three, or four doses of TY21a live oral typhoid vaccine in enteric-coated capsules: a field trial in an endemic area. J Infect Dis 1989; 159: 766769.
  • 24
    Cooper B, Detora L. Menveo ®: a novel quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135 and Y. Expert Rev Vaccines 2011; 10: 2133.
  • 25
    Perrett KP, Snape MD, Ford KJ, John TM, Yu L-MM, Langley JM, McNeil S, Dull PM, Ceddia F, Anemona A, Halperin SA, Dobson S, Pollard AJ. Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants. Pediatr Infect Dis J 2009; 28: 186193.
  • 26
    Recommendation of the Advisory Committee on Immunization Practices (ACIP) for Use of Quadrivalent Meningococcal Conjugate Vaccine (MenACWY-D). Among Children Aged 9 Through 23 months at Increased Risk for Invasive Meningococcal Disease. MMWR Morb Mortal Wkly Rep 2011; 60: 13911392.
  • 27
    Lobato MN, Hopewell PC. Mycobacterium tuberculosis infection after travel to or contact with visitors from countries with a high prevalence of tuberculosis. Am J Respir Crit Care Med 1998; 158: 18711875.
  • 28
    Hendel-Paterson B, Swanson SJ. Pediatric travelers visiting friends and relatives (VFR) abroad: illnesses, barriers and pre-travel recommendations. Travel Med Infect Dis 2011; 9: 192203.
  • 29
    Rodrigues LC, Diwan V, Wheeler J. Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis. Int J Epidemiol 1993; 22: 11541158.
  • 30
    Colditz GA, Berkey CS, Mosteller F, Brewer TF, Wilson ME, Burdick E, Fineberg HV. The efficacy of bacillus calmette-guérin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics 1995; 96: 2935.
  • 31
    Bothamley GH, Cooper E, Shingadia D, Mellanby A. Tuberculin testing before BCG vaccination. 2003; (December 2005):2003–5.
  • 32
    Centers for Disease Control and Prevention. CDC Health Information for International Travel 2012. New York: Oxford University Press, 2012.
  • 33
    Yellow fever vaccination requirements and recommendations. In: International Travel and Health, ed. World Health Organization. Geneva: WHO Press, 2011; 200231.
  • 34
    Warrell MJ. Emerging aspects of rabies infection: with a special emphasis on children. Curr Opin Infect Dis 2008; 21: 251257.
  • 35
    Rupprecht CE, Hanlon CA, Hemachudha T. Rabies re-examined. Lancet Infect Dis 2002; 2: 327343.
  • 36
    Warrell MJ. Intradermal rabies vaccination: the evolution and future of pre- and post-exposure prophylaxis. Curr Top Microbiol Immunol 2012; 351: 139157.
  • 37
    Hanna JN, Ritchie SA, Phillips DA, Shield J, Bailey MC, Mackenzie JS, Poidinger M, McCall BJ, Mills PJ. An outbreak of Japanese encephalitis in the Torres Strait, Australia, 1995. Med J Malaysia 1996; 165: 256260.
  • 38
    Hanna J, Ritchie S, Phillips D, Lee J, Hills S, van den Hurk A, Pyke AT, Johansen CA, Mackenzie JS. Japanese encephalitis in north Queensland, Australia, 1998. Med J Malaysia 1999; 170: 533536.
  • 39
    Wilder-Smith A, Halstead SB. Japanese encephalitis: update on vaccines and vaccine recommendations. Curr Opin Infect Dis 2010; 23: 426431.
  • 40
    Halstead SB, Thomas SJ. New vaccines for Japanese encephalitis. Curr Infect Dis Rep 2010; 12: 174180.
  • 41
    Dubischar-Kastner K, Kaltenboeck A, Klingler A, Jilma B, Schuller E. Safety analysis of a Vero-cell culture derived Japanese encephalitis vaccine, IXIARO (IC51), in 6 months of follow-up. Vaccine 2010; 28: 64636469.
  • 42
    Dubischar-Kastner K, Eder S, Buerger V, Gartner-Woelfl G, Kaltenboeck A, Schuller E, Tauber E, Klade C. Long-term immunity and immune response to a booster dose following vaccination with the inactivated Japanese encephalitis vaccine IXIARO, IC51. Vaccine 2010; 28: 51975202.
  • 43
    Halstead SB, Thomas SJ. Japanese encephalitis: new options for active immunization. Clin Infect Dis 2010; 50: 11551164.
  • 44
    Steffen R. Epidemiology of traveler's diarrhea. Clin Infect Dis 2005; 41: (Suppl. 8): S536540.
  • 45
    Greenwood Z, Black J, Weld L, O'Brien D, Leder K, Von Sonnenburg F, Pandey P, Schwartz E, Connor BA, Brown G, Freedman DO, Torresi J, for the GeoSentinel Surveillance Network. Gastrointestinal infection among international travelers globally. J Travel Med 2008; 15: 221228.
  • 46
    Swaminathan A, Torresi J, Schlagenhauf P, Thursky K, Wilder-Smith A, Connor BA, Schwartz E, Vonsonnenberg F, Keystone J, O'Brien DP, GeoSentinel Network. A global study of pathogens and host risk factors associated with infectious gastrointestinal disease in returned international travellers. J Infect 2009; 59: 1927.
  • 47
    Hill DR, Beeching NJ. Travelers' diarrhea. Curr Opin Infect Dis 2010; 23: 481487.
  • 48
    Shah N, DuPont HL, Ramsey DJ. Global etiology of travelers' diarrhea: systematic review from 1973 to the present. Am J Trop Med Hyg 2009; 80: 609614.
  • 49
    Mackell S. Traveler's diarrhea in the pediatric population?: Etiology and impact. Clin Infect Dis 2005; 41: (Suppl. 8): 547552.
  • 50
    Jelinek T, Kollaritsch H. Vaccination with Dukoral against travelers' diarrhea (ETEC) and cholera. Expert Rev Vaccines 2008; 7: 561567.
  • 51
    Dupont HL, Ericsson CD, Farthing MJ, Gorbach S, Pickering LK, Rombo L, Steffen R, Weinke T. Expert review of the evidence base for prevention of travelers' diarrhea. J Travel Med 2009; 16: 149160.
  • 52
    Peltola H, Siitonen A, Kataja M, Kyronseppa H. Prevention of travelers' diarrhea by oral B-subunit/whole-cell cholera vaccine. Lancet 1991; 338: 12851289.
  • 53
    Frech SA, Dupont HL, Bourgeois AL, McKenzie R, Belkind-Gerson J, Figueroa JF, Okhuysen PC, Guerrero NH, Martinez-Sandoval FG, Meléndez-Romero JH, Jiang ZD, Asturias EJ, Halpern J, Torres OR, Hoffman AS, Villar CP, Kassem RN, Flyer DC, Andersen BH, Kazempour K, Breisch SA, Glenn GM. Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial. Lancet 2008; 14: 20192025.
  • 54
    Otto W, Najnigier B, Stelmasiak T, Robins-Browne RM. Randomized control trials using a tablet formulation of hyperimmune bovine colostrum to prevent diarrhea caused by enterotoxigenic Escherichia coli in volunteers. Scand J Gastroenterol 2011; 46: 862868.
  • 55
    DuPont HL, Ericsson CD, Farthing MJG, Gorbach S, Pickering LK, Rombo L, Steffen R, Weinke T. Expert review of the evidence base for self-therapy of travelers' diarrhea. J Travel Med 2009; 16: 161171.
  • 56
    Tribble DR, Sanders JW, Pang LW, Mason C, Pitarangsi C, Baqar S, Armstrong A, Hshieh P, Fox A, Maley EA, Lebron C, Faix DJ, Lawler JV, Nayak G, Lewis M, Bodhidatta L, Scott DA. Traveler's diarrhea in Thailand: randomized, double-blind trial comparing single-dose and 3-day azithromycin-based regimens with a 3-day levofloxacin regimen. Clin Infect Dis 2007; 1: 338346.
  • 57
    Cottreau J, Baker S, DuPont H, Garey K. Rifaximin: a nonsystemic rifamycin antibiotic for gastrointestinal infections. Expert Rev Anti Infect Ther 2010; 8: 747760.
  • 58
    Koo HL, DuPont HL. Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases. Curr Opin Gastroenterol 2010; 26: 1725.
  • 59
    Muniyappa P, Gulati R, Mohr F, Hupertz V. Use and safety of rifaximin in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2009; 49: 400404.
  • 60
    Kimani EW, Vulule JM, Kuria IW, Mugisha F. Use of insecticide-treated clothes for personal protection against malaria: a community trial. Malar J 2006; 5: 63. doi:10.1186/1475-2875-5-63.
  • 61
    Goodyer LI, Croft AM, Frances SP, Hill N, Moore SJ, Onyango SP, Debboun M. Expert review of the evidence base for arthropod bite avoidance. J Travel Med 2010; 17: 182192.
  • 62
    Fradin MS, day JF. Comparative efficacy of insect repellents against mosquito bites. N Engl J Med 2002; 347: 1318.
  • 63
    Fradin M. Mosquitoes and mosquito repellents: a clinician's guide. Ann Intern Med 1998; 128: 931940.
  • 64
    Veltri J, Osimitz T, Bradford D. Retrospective analysis of calls to poison control centers resulting from exposure to the insect repellent N,N-diethyl-m-toluamide (DEET) from 1985–1989. J Toxicol Clin Toxicol 1994; 32: 116.
  • 65
    Overbosch D, Schilthuis H, Bienzle U, Behrens RH, Kain KC, Clarke PD, Toovey S, Knobloch J, Nothdurft HD, Shaw D, Roskell NS, Chulay JD; Malarone International Study Team. Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: results from a randomized, double-blind study. Clin Infect Dis 2001; 33: 10151021.
  • 66
    Ohrt C, Richie TL, Widjaja H, Shanks GD, Fitriadi J, Fryauff DJ, Handschin J, Tang D, Sandjaja B, Tjitra E, Hadiarso L, Watt G, Wignall FS. Mefloquine compared with doxycycline for the prophylaxis of malaria in Indonesian soldiers. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1997; 126: 963972.
  • 67
    Schlagenhauf P, Tschopp A, Johnson R, Nothdurft HD, Beck B, Schwartz E, Herold M, Krebs B, Veit O, Allwinn R, Steffen R. Tolerability of malaria chemoprophylaxis in non-immune travellers to sub-Saharan Africa: multicentre, randomised, double blind, four arm study. BMJ 2003; 327: 1078.
  • 68
    Jacquerioz FA, Croft AM. Drugs for preventing malaria in travellers. Cochrane Database Syst Rev 2009; (4): CD006491. doi:10.1002/14651858.CD006491.pub2.
  • 69
    Schlagenhauf P, Adamcova M, Regep L, Schaerer MT, Bansod S, Rhein H-G. Use of mefloquine in children – a review of dosage, pharmacokinetics and tolerability data. Malar J 2011; 10: 292.
  • 70
    Schlagenhauf P, Adamcova M, Regep L, Schaerer MT, Rhein H-G. The position of mefloquine as a 21st century malaria chemoprophylaxis. Malar J 2010; 9: 357.
  • 71
    Sinclair D, Gogtay N, Brand F, Olliaro P. Artemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malaria. Cochrane Database Syst Rev 2011; (7): CD008492.
  • 72
    Makanga M, Bassat Q, Falade CO, Premji ZG, Krudsood S, Hunt P, Walter V, Beck HP, Marrast AC, Cousin M, Rosenthal PJ. Efficacy and safety of artemether-lumefantrine in the treatment of acute, uncomplicated plasmodium falciparum malaria: a pooled analysis. Am J Trop Med Hyg 2011; 85: 793804.
  • 73
    Four Artemisinin-Based Combinations (4ABC) Study Group. A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in african children: a randomized trial. PLoS Med 2011; 8: e1001119.
  • 74
    Litman RS, Soin K, Salam A. Chloral hydrate sedation in term and preterm infants: an analysis of efficacy and complications. Anesth Analg 2010; 110: 739746.